1. Scrip
  2. >>Therapy Areas
  3. >>Musculoskeletal

Interview: Mereo All Set For Key Setrusumab Data

 
• By Kevin Grogan

Although far from a one-product company, data in Q4 will be key to whether the brittle bone drug could become a blockbuster for the UK NASDAQ-listed biotech.

Q4 2019
End of the year will be pivotal for Mereo • Source: Shutterstock

Mereo BioPharma Group PLC is gearing up for a pivotal fourth quarter which will see the readout of data on the UK company's key asset, setrusumab for brittle bone disease.

In an interview with Scrip, CEO Denise Scots-Knight noted that earlier this year, Mereo posted positive six-month data from the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Musculoskeletal

More Pressure on Elevidys As The EU’s CHMP Says ‘No’

 
• By Alexandra Shimmings

Just days after Roche stopped shipments of the DMD gene therapy following safety concerns raised by two patient deaths, its EU approval application has hit a block.

Capricor Gets Complete Response For DMD Cell Therapy

 
• By Joseph Haas

Seven weeks before its action date, Capricor got an FDA complete response for cell therapy deramiocel in DMD-related cardiomyopathy. It has a Phase III study nearing readout, though.

Ultragenyx and Mereo Still Confident Despite Setrusumab Slip Up

 
• By Kevin Grogan

The osteogenesis imperfecta drug stumbled in a second interim analysis.

Taiho’s Oral, Mutation-Agnostic DMD Candidate Misses Phase III Endpoint

 
• By Lisa Takagi

The oral, twice-daily candidate was expected to control decline in motor function in DMD patients regardless of their gene mutations.

More from Therapy Areas

Lilly’s Verzenio Scores First OS Improvement In Key Breast Cancer Setting In Decades

 
• By Alaric DeArment

The drugmaker announced topline results for the CDK4/6 inhibitor in early HR-positive, HER2-negative breast cancer, giving it a competitive edge over Novartis’s Kisqali.

Novo Adds Another Prong To Its RNA Ambitions With Replicate Deal

 
• By Jessica Merrill

Replicate is a clinical-stage company developing a next-generation self-replicating RNA technology. CEO Nathanial Wang talked to Scrip about the deal.

Psychedelic Drug Development Shows Promise, But Market Path Remains Steep

 
• By Sushmita Panda

With late-stage trials advancing and regulatory guidance in place, psychedelic medicines are nearing a pivotal moment in their path to market. Success will hinge on overcoming clinical, logistical and commercial challenges.